1. Home
  2. CERT vs NVCR Comparison

CERT vs NVCR Comparison

Compare CERT & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Certara Inc.

CERT

Certara Inc.

N/A

Current Price

$11.84

Market Cap

1.4B

Sector

Technology

ML Signal

N/A

Logo NovoCure Limited

NVCR

NovoCure Limited

N/A

Current Price

$11.50

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CERT
NVCR
Founded
2008
2000
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
CERT
NVCR
Price
$11.84
$11.50
Analyst Decision
Buy
Buy
Analyst Count
13
7
Target Price
$12.68
★ $26.14
AVG Volume (30 Days)
★ 2.6M
1.8M
Earning Date
11-05-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 87.50
21.79
EPS
★ N/A
N/A
Revenue
$418,838,000.00
★ $655,353,000.00
Revenue This Year
N/A
$12.95
Revenue Next Year
$3.64
$9.33
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 8.75
8.28
52 Week Low
$4.45
$9.82
52 Week High
$12.61
$21.45

Technical Indicators

Market Signals
Indicator
CERT
NVCR
Relative Strength Index (RSI) 65.90 31.84
Support Level $6.26 $10.14
Resistance Level $12.61 $18.43
Average True Range (ATR) 0.65 0.83
MACD 0.01 -0.18
Stochastic Oscillator 68.74 3.36

Price Performance

Historical Comparison
CERT
NVCR

About CERT Certara Inc.

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Share on Social Networks: